KWKaren Walsh

Karen Walsh

*This is an algorithmically generated author record based on publicly available information.

Karen Walsh has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Into the Mind of a Malicious Actor

    by Karen Walsh

    Malicious actors are typically financially motivated, looking to deploy attacks that have a high return on investment. They often target small and mid-size businesses (SMBs) who have fewer staffing and financial resources for security. This chapter outlines data breach risks and costs as well as common attack types.

  • Open Access

    Perioperative Outcomes of Patients with Bleeding Disorders Undergoing Major Surgery at an Academic Hemophilia Treatment Center

    by Ruben Rhoades, Zachary French, Amy Yang, Karen Walsh, Douglass A. Drelich, Steven E. McKenzie

    Persons with bleeding disorders (PwBD) are at high risk for bleeding with invasive procedures. However, the risk of bleeding in PwBD undergoing major surgery and outcomes of patients managed perioperatively at a hemophilia treatment center (HTC) are not well described. We performed a retrospective review of surgical outcomes among PwBD undergoing major surgery between January 1st, 2017 and December 31st, 2019 at the Cardeza Foundation Hemophilia and Thrombosis Center in Philadelphia, PA. The primary outcome was postoperative bleeding, assessed according to the ISTH-SSC's 2010 definition. Secondary outcomes included use of unplanned postoperative hemostatic therapy, LOS, and 30-day readmission rate. Results were compared to non-PwBD population from a surgical database, matched for surgery, age, and sex. During the study period, 50 PwBD underwent 63 major surgeries. The most common diagnoses were VWD (64%) and hemophilia A (20.0%). The most common surgical procedure category was orthopedic (33.3%), predominantly arthroplasties. Postoperatively,4.8% of procedures were complicated by major bleeding and 1.6% by non-major bleeding. The mean LOS was 1.65 days, and 30-day readmission rate was 1.6%. In comparison to matched, non-PwBD patients in a national surgical database undergoing the same procedures, study patients had a similar rate of bleeding complications per procedure (5.0% vs 1.04% P = .071, Fisher's exact test). PwBD undergoing major surgeries have low rates of major bleeding when receiving comprehensive care at an HTC. Bleeding and hospital readmission rates were similar to non-PwBD baseline in a large database.


  • Total cost of care of hematologic malignancy episodes versus target price under the Oncology Care Model.

    by Jennifer Nguyen, Karen Walsh, Vittorio Maio, Seojin Park, Shivangi Patel, Scott W. Keith, Nathan Handley, Valerie Pracilio Csik

    67 Background: In 2016 the Center for Medicare & Medicaid Innovation developed the Oncology Care Model (OCM) in response to increasing cancer-attributable cost for medical services and prescription drugs. Under the OCM, practices are incentivized to provide higher quality and coordinated care through a dual payment model including a Monthly Enhanced Oncology Services (MEOS) payment and potential for performance-based payment (PBP), where PBPs are based on a practice’s total cost of care (TCOC) savings amount relative to a risk-adjusted target amount. On average, hematologic malignancies are burdened with higher costs than other cancer types. The objective of this study was to evaluate whether TCOC and target price were aligned in OCM hematologic malignancy episodes. Methods: This was a retrospective cross-sectional study using OCM claims data from an urban, academic, National Cancer Institute-designated cancer center. The analysis was conducted at the episode level from performance period 1 to 4 (time period: 7/1/2016 to 7/1/2018). A logistic regression with a generalized estimating equation (GEE) was used to assess the likelihood of episode characteristics and TCOC to exceed the target price. A linear regression with a GEE was used to evaluate the mean difference between TCOC and target price episodes. Results: Of the 516 episodes of hematologic malignancies included in the analysis, 55.2% were male and 26.9% were 70-74 years old. 283 episodes (54.8%) exceeded target price. Several parameters were found statistically significantly associated with the likelihood of exceeding and not exceeding target price (Table). Largest positive mean difference from target price was in episodes with Medicare Part D drug use ($24,344) and largest negative difference in radiation use (-$33,758). Conclusions: We found a substantial misalignment between TCOC and target price for hematologic malignancy episodes, with a majority of episodes exceeding target price. This study adds to the existing evidence on the lack of adequate adjustment to the OCM target price. As the OCM concludes, our findings identify areas of opportunity for consideration in future payment models, such as re-evaluating the target price methodology, inclusion of drug costs and adequate adjustment for select parameters (history of chemotherapy, novel therapy, and Part B and D expenditures).

  • Open Access

    Estimating the National Population of Hospitalized Chronic Baclofen Users: A Cross-Sectional Analysis of a Commercial Claims Database

    by Natalie Schmitz, Margaret Artz, Karen Walsh, Sandeep Gaudana, James Cloyd, John Schrogie, Robert Kriel

    Background Baclofen is an effective treatment for spasticity. Abrupt cessation of intrathecal (IT) or oral baclofen risks the development of withdrawal symptoms; however, the magnitude of the problem is unknown. Objectives The aims for this study were as follows: (1) using an administrative claims database, estimate the number of patients in the United States on baclofen, and (2) estimate the annual percent hospitalized pediatric and adult populations consequently at risk for interruption of chronic baclofen therapy. Methods Using 2011–2014 data representing commercially insured individuals, patients were selected based on insurance coverage; evidence of a baclofen claim; and hospitalization. All patients hospitalized while receiving chronic baclofen were assumed to be at risk for baclofen discontinuation. Yearly counts were determined and then extrapolated to national estimates using census data. Results Extrapolating from the claims database, oral or IT baclofen was prescribed annually to 33,061 or 1486 patients ≤ 18 years, and 654,294 or 7084 patients 19–64 years, respectively. The estimated national mean number of at-risk hospitalizations per year for patients aged 19–64 years on chronic oral or IT baclofen was 31,116 and 3774, respectively; patients ≤ 18 years numbered 4691 and 959, respectively. The mean percent of patients hospitalized per year was 42% in those ≤ 18 years receiving IT baclofen compared with 30% in adults, and 3–10% in the populations receiving oral baclofen. Conclusions Extrapolation from an administrative claims database was used to estimate the national number and demographics of hospitalized chronic baclofen users. Patients ≤ 18 years receiving IT baclofen were at highest risk of withdrawal due to a high occurrence of hospitalization.


  • Breast Cancer Stage Is Associated With Exceeding Target Price in the Oncology Care Model

    by Ryan B. Thomas, Vittorio Maio, Anna Chen, Seojin Park, Dexter Waters, Scott W. Keith, Karen Walsh, Nathan Handley, Valerie P. Csik

    PURPOSE:To explore mean difference between Oncology Care Model (OCM) total costs and target price among breast cancer episodes by stage under the Centers for Medicare and Medicaid Services OCM paym...


  • Open Access

    Can the role of the nurse as surgical assistant add value in the Australian public health care sector?

    by Toni Hains, Ano Navaratnam, Andrew O’bRien, Karen Walsh, Jane Nielsen, Susan Firth

    Registered nurses (RNs) and subsequently nurse practitioners (NP) have practiced the role of surgical assistant in the Australian health care system for more than 30 years. The Australian College of Perioperative Nurses (ACORN) has a statement outlining the responsibilities of nurses undertaking the role. Australian research corroborates international research that non-medical surgical assistants (i.e. surgical assistants who are not medical doctors) have equivalent patient outcomes to their medical counterparts. While the majority of nurses as surgical assistants work in the private sector in the Australian health care system4, the role is underutilised in the Australian public health care sector. There is an opportunity for nurses as surgical assistants to add value in the public health care sector. The public sector nurse surgicalassistant model is advantageous in surgical specialties where the surgical assistant requires highly specialised skills. These skills often require a protracted learning curve which is not suited to transient junior medical personnel. One specialty particularly suited to nurses as surgical assistants is in robotic-assisted surgery.